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aged 2 4/12 t o 17 y. old (X r SD: 9.4 f 3.9). They all received antithyroid drugs a s i n i t i a l treatment. Thirty s i x patients followed for 3 t o 14 y., could be reevaluated with T , T3 and TSH and/or TRH a f t e r treatment i n a t least 2 ocassions? a t short-term (ST: 1-2 y. post onset of treatment) and a t longterm (LT:mre than 3 y.; ji f 6.23 f 3.3). Twenty three patients (64%) remained hyperthyroid (Hper) between ST and LT and 9(25%) hypo o r euthyroid (Hpo/Eu) between ST and LT; only 4 (11%) changed from Hper a t ST t o Hpo/Eu a t LT. Thus, 89% did not rcdfj' t h e i r thyroid function between ST and LT. The period of the evolution f m n Hper t o Hpo/Eu showed two distinct populations,one with a X i SD of 17.3 f 3.8 mnths and another with ji i SD of 9.4 i 2.5 y. I t is concluded that Amluationof thyroid flvlction a t ST is usefhl to p d i c t t h e i r status a t LT since 9% of patients showed no variations. Since patients who changed thyroid ficticn f m n Hper t o Hpo/Eu a t ST did it in ji 17.3 months it is advisable t o w a i t up t o t h i s time t o select another therapeutic options. I f Hper persists the possibility of I 131 administration should be considered t o avoid the excessively long treatment required by the unrelenting course of t h i s disease. UTPH. Results on who lemount mamnary gland indicated that there was: a ) not s i s i f i c a n t difference among groups vs control i n the number of m a m~l y gland ducts. b) a s i w i f i c a n t increase i n n n b~ of terminal end buds (TEB) i n group I1 vs I ( p <0.0035) and 111 (p(0.0035) or I 1 vs IV (p<0.0005). c ) a siflificant increase i n n u d e r of alveoli of group I I ( p < 0.0005) and I11 (p <0.0005) vs control. W e can conclude f m n these studies that UTPH inhibited E + P action on TEB development while had no effect on ducts and alveoli. 
PULMONARY FINDINGS IN POS?MORTEM MAMINATIONS OF PEDIATRIC ACQUIRED LWJhODEFICIENCI SINDROME (AIDS

